1 / 22

Beyond ePrescribing

Beyond ePrescribing. Factors Influencing Patient Safety in Medical Group Practices - September 26 th , 2007 AHRQ 2007: Improving Healthcare, Improving Live Larry Garber, M.D. – Medical Director for Informatics. Overview. Sources of Adverse Drug Events (ADE’s) in the ambulatory setting

sarai
Download Presentation

Beyond ePrescribing

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Beyond ePrescribing Factors Influencing Patient Safety in Medical Group Practices - September 26th, 2007 AHRQ 2007: Improving Healthcare, Improving Live Larry Garber, M.D. – Medical Director for Informatics

  2. Overview • Sources of Adverse Drug Events (ADE’s) in the ambulatory setting • Reducing anticoagulant-related ADE’s • Future plans and barriers to reducing ADE’s

  3. Sources of ADE Information Field, TS et al. JAMIA 2004;52:1349-1354.

  4. ADE Rates in the Ambulatory Setting • ADEs:50 per 1000 person-years • Preventable ADEs: 14 per 1000 person-years (28%) • Extrapolated to total Medicare 65+:1,446,949 ADEs per year438,046 preventable ADEs/year • This is likely to be an underestimate Gurwitz JH et al JAMA 2003;289:1107-1116

  5. Financial Cost of ADE’s Field TS, et al Medical Care 2005;43:1171-6

  6. Financial Cost of ADE’s • Increase in costs after an ADE: $1310Increase after a preventable ADE: $1983 • Extrapolated to 1000 adults age 65+Costs per year to treat preventable ADEs:$27,365

  7. ADE Severity in the Ambulatory Setting

  8. Severity & Preventability Of less serious events Of fatal & life-threatening events Preventable 52% Preventable 20%

  9. Source of Errors

  10. So where do you start?

  11. Fallon Approach to Preventing ADE’s • First target the Fatal & Life-Threatening preventable ADE’s • Warfarin • Then do a system-wide solution for the others

  12. Preventing Warfarin ADE’s • Ordering/Prescribing • ePrescribing with drug interaction checking • Simplified referrals to Anticoagulation Clinic • Monitoring • Converted Anticoagulation Clinic to Epic’s EHR • Simplified tracking of lab no-shows

  13. Full dosing information is entered and available to be seen by all physicians and staff Date of next INR is entered to trigger tickler system

  14. INR Reminder automatically appears in the Anticoagulation Clinic In-basket on the patient’s due date, and doesn’t disappear until the due date is changed

  15. Preventing Other ADE’s • Use probabilistic risk assessment to: • characterize systemic and behavioral elements that increase of ADE’s during ordering/monitoring • identify potentially high-yield and likely-to-be-successful interventions • Estimate likelihood that interventions at any given step would be successful in reducing errors at that step • Select interventions for implementation Field TS et al AHRQ Grant # 1P20HS017109-01

  16. Barriers to preventing ADE’s • Most organizations don’t have EHR’s • ePrescribing doesn’t solve the monitoring problem • Many EHR’s don’t currently have the functionality to provide alerts for missing events without being in the context of a patient encounter • MD compliance • Time and money required to build interventions

  17. Summary: • ADEs are common and often preventable • Types of errors suggest focus on prescribing and monitoring • Provision of information to physicians and assistants at right time, right place… • Use of automated tickler systems • Costs are high and savings from preventing ADEs could partially offset costs of interventions

  18. Questions? Larry Garber, M.D. Lawrence.Garber@FallonClinic.org Special thanks to Terry Field, PhD and Jerry Gurwitz, M.D. for their assistance on this presentation and never-ending work to study and prevent ADE’s

More Related